



17W

PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Alexandria, VA 22313, on

*Jane A. Walker*  
Jane A. Walker

July 14, 2004  
Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Rothenberg  
Application No.: 10/759,288  
Filed: January 16, 2004  
Title: **REGULATION OF ALLERGEN INDUCED GENE**  
Art Unit: 1644  
Examiner: Unknown  
Conf. No.: 7158  
Atty. Docket No.: CMC-163

Cincinnati, Ohio

July 14, 2004

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**FILED PURSUANT TO 37 CFR §§ 1.56 AND 1.97-1.98**

Sir:

In accordance with the duty of candor and good faith imposed by 37 C.F.R. §1.56, and the means of complying with that duty according to 37 C.F.R. §§1.97 and 1.98. Applicant calls the references listed on the attached PTO-1449 form to the attention of the United States Patent and Trademark Office in connection with the

above-identified patent application. These references were cited in an International Search Report dated June 14, 2004 received for a related foreign application. Applicant has enclosed a copy of the required cited references as well as the Search Report.

No representation is made that the cited art is the only art or that the cited art represents the best art.

The Examiner is urged to consider the cited references and to make an independent decision with respect to their materiality.

**Certification Under C.F.R. § 1.97(e)(2)**

Each item of information contained in the Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Supplemental Information Disclosure Statement.

**Certification Under 37 C.F.R. § 1.704(d)**

Each item contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application and was not received by any person designated in § 1.56(c) more than thirty days prior to the filing of the information disclosure statement.

Applicant does not believe that any fees are due in connection with this submission. However, if such fees are necessary, the Commissioner is authorized to charge any such fees to Deposit Account 23-3000.

Respectfully submitted,

WOOD, HERRON & EVANS, L.L.P.

By: Beverly A. Lyman  
Beverly A. Lyman, Ph.D.  
Reg. No. 41,961

Wood, Herron & Evans, L.L.P.  
2700 Carew Tower  
Cincinnati, OH 45202  
513 241-2324  
513 421-7269 facsimile

K:\CMC\162\IDS Supp.wpd

SUBSTITUTE FORM PTO-1449

(MODIFIED)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
CMC/163SERIAL NO.  
10/759,288

JUL 16 2004

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT  
RothenbergFILING DATE  
01/16/04GROUP  
1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER							ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A.A	6	1	4	3	8	7	1	11/07/00	Bonnefoy et al.	530	351	11/12/97
	A.B												
	A.C												
	A.D												
	A.E												
	A.F												
	A.G												
	A.H												
	A.I												
	A.J												
	A.K												

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	A.L	WO 0036103	06/22/00	PCT	C12N	15/12	NA
	A.M	WO 02102399	12/27/02	PCT	A61K	38/00	NA
	A.N	WO 03030824	04/17/03	PCT	A61K		NA
	A.O	WO 03045332	06/05/03	PCT	A61K		NA
	A.P	WO 9494680	03/03/94	PCT	C12N	15/24	NA
	A.Q	WO 9803654	01/29/98	PCT	C12N	15/24	NA

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	A.R	Granness A., et al., <u>Protein Kinase C and ERK Activation Are Required for TFF-peptide-stimulated Bronchial Epithelial Cell Migration and Tumor Necrosis Factor-<math>\alpha</math>-induced Interleukin-6 (IL-6) and IL-8 Secretion</u> , The Journal of Biological Chemistry, 277:18440-18446 (2002)
	A.S	Oertel, M. et al., <u>Trefoil Factor Family-Peptides Promote Migration of Human Bronchial Epithelial Cells: Synergistic Effect with Epidermal Growth Factor</u> , American Journal of Respiratory Cell and Molecular Biology Vol. 25 (2001) pp. 418-424
	A.T	PCT, <u>International Search Report</u> , PCT/US2004/O01140, mailed 06/14/04, 5 pg.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
CMC/163SERIAL NO.  
10/759,288INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT  
RothenbergFILING DATE  
01/16/04GROUP  
1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B.A						
	B.B						
	B.C						
	B.D						
	B.E						
	B.F						
	B.G						
	B.H						
	B.I						
	B.J						
	B.K						

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	B.L						
	B.M						
	B.N						
	B.O						
	B.P						
	B.Q						

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	B.R	Williams, G.R. et al., <u>Trefoil facotr family domain peptides</u> , Virchows Arch (1997) 431:299-304
	B.S	
	B.T	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered.  
Include a copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)